Levosimendan and pulmonary hypertension.
Yuksel
Y
Cavusoglu
Ayse
A
Beyaztas
Alparslan
A
Birdane
Necmi
N
Ata
D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006835:Hydrazones / Q000009:adverse effects / Q000627:therapeutic use*; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology; D011651:Pulmonary Artery / Q000187:drug effects* / Q000503:physiopathology; D011724:Pyridazines / Q000009:adverse effects / Q000627:therapeutic use*; D000077464:Simendan; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016276:Ventricular Function / Q000187:drug effects
D000959:Antihypertensive Agents; D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D014665:Vasodilator Agents; D000077464:Simendan